#linagliptin brands

[thelotusbiotech]

Stress Management Strategies for Balanced Blood Sugar Levels

Maintaining healthy blood sugar levels is crucial for overall well-being, especially for individuals diagnosed with Type 2 diabetes. While factors like diet, exercise, and medication play vital roles, managing stress often takes a backseat despite its significant impact on blood glucose control. This blog delves into Type 2 diabetes, explores the common symptoms, and emphasizes the importance of stress management in achieving balanced blood sugar levels. 

What is Type 2 Diabetes?

Type 2 diabetes is a chronic condition characterized by high blood sugar levels. While the body naturally produces insulin, a hormone that helps cells absorb glucose (sugar) from the bloodstream for energy, in Type 2 diabetes, the body either becomes resistant to the effects of insulin or doesn't produce enough. This results in excess sugar circulating in the blood, leading to various health complications if left unmanaged.

Common Symptoms of Type 2 Diabetes:

Frequent urination

Excessive thirst

Unexplained weight loss or fatigue

Blurred vision

Slow-healing wounds

Tingling or numbness in hands and feet

How Does Stress Affect Blood Sugar Levels?

Stress triggers the release of hormones like cortisol and glucagon, which elevate blood sugar levels. This is a natural response meant to provide the body with energy during stressful situations. However, chronic stress can lead to persistently high blood sugar, disrupting insulin sensitivity and making it harder for the body to regulate blood glucose.

Various studies conducted on the effects of overeating due to stress on blood sugar levels also suggest a direct correlation between type 2 diabetes and binge eating. Some people tend to eat more when they are under stress, which ultimately leads to weight gain. The result? Increased resistance to insulin production leads to a stagnation of sugar levels in the blood. 

Stress Management Strategies for Balanced Blood Sugar:

Regular Exercise: Physical activity helps burn off excess glucose, improves insulin sensitivity, and reduces stress. Aim for at least 150 minutes of moderate-intensity or 75 minutes of vigorous weekly exercise.

Healthy Diet: Prioritize whole foods like fruits, vegetables, and lean proteins while limiting processed foods, sugary drinks, and saturated fats. These dietary changes can significantly impact blood sugar control.

Mindfulness and Relaxation Techniques: Practices like meditation, yoga, deep breathing, and progressive muscle relaxation can reduce stress and promote overall well-being. Dedicate 10-20 minutes daily to these activities for noticeable improvements.

Quality Sleep: Aim for 7-8 hours of sleep each night. Sleep deprivation can worsen insulin sensitivity and contribute to higher blood sugar levels. Establish a regular sleep schedule and create a relaxing bedtime routine.

Social Support: Connecting with loved ones, joining support groups, and seeking professional help for managing stress can provide invaluable emotional support and guidance.

Manage Type 2 Diabetes Effectively with Ondero 5mg Linagliptin Tablets.

Ondero 5mg Linagliptin Tablets are a prescription medication used to manage Type 2 diabetes. Linagliptin belongs to a class of drugs called DPP-4 inhibitors, which enhance the incretin effect. Incretins are natural gut hormones that stimulate insulin secretion and reduce glucagon production after eating, lowering blood sugar levels.

Ondero Linagliptin 5 mg is typically taken once daily with or without food. It is important to note that it is not a substitute for a healthy lifestyle or other medications prescribed for diabetes management. Always consult your doctor before starting Ondero 5mg or any other medicines.

Action Mechanism:

Diabetes medication linagliptin tablets offer a potent solution for type 2 diabetes management by targeting the core of the issue: blood sugar control. Its active ingredient, Linagliptin, unlocks a two-pronged approach:

Enhanced Insulin Secretion: Linagliptin stimulates the pancreas to release more insulin, the essential hormone regulating blood sugar. This ensures your body has the tools to prevent uncontrolled sugar spikes after meals.

Reduced Glucose Production: The drug also curbs the liver's ability to generate excess glucose, further preventing blood sugar imbalances.

This combined action results in improved glycemic control, a crucial factor in managing diabetes. 

Benefits:

Minimize the risk of serious complications: Stable blood sugar levels translate to a lower risk of diabetes-related issues like kidney damage, nerve problems, vision loss, and heart disease.

Support a healthier lifestyle: Effective blood sugar management empowers you to embrace a more active life, contributing to overall well-being. Ondero 5mg empowers you to take control of your diabetes and adopt a healthier future.

Finding the Right Balance:

Managing Type 2 diabetes effectively requires a multi-faceted approach. While medication like Ondero 5mg Linagliptin or Linagliptin 5mg substitutes can be valuable, incorporating stress management strategies into your daily routine is crucial for maintaining balanced blood sugar levels and improving overall health. Remember, prioritising healthy habits, managing stress effectively, and working closely with your doctor and healthcare team are vital to achieving and maintaining optimal well-being with Type 2 diabetes. 

Disclaimer:

Though this post contains authentic information from verified sources and aims to educate the masses on bodily disorders and potential medications used in their treatment, there is always a minute possibility of human error. It’s strongly advised and recommended that you consult your healthcare physician before making any health decisions. Kindly refrain from self-administration of any medications.

[usmedilife12health]

Linagliptin Tablets

Linagliptin is a medication that treats Type 2 diabetes by increasing insulin levels in your body.

It can also reduce how much sugar gets released into your blood.

A healthcare provider may recommend changes to your diet and exercise if you take this medication. It comes in a tablet form.

What is this medication?

LINAGLIPTIN (lin a GLIP tin) treats type 2 diabetes.

It works by increasing insulin levels in your body, which decreases your blood sugar (glucose).

It also reduces the amount of sugar released into your blood. Changes to diet and exercise are often combined with this medication.

This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.

COMMON BRAND NAME(S): Tradjenta

What should I tell my care team before I take this medication?

They need to know if you have any of these conditions:

Diabetic ketoacidosis

Type 1 diabetes

An unusual or allergic reaction to linagliptin drug class, other medications, foods, dyes, or preservatives

Pregnant or trying to get pregnant

Breast-feeding

How should I use this medication?

Take this medication by mouth with a glass of water. Follow the directions on the prescription label.

You can take it with or without food. Take your dose at the same time each day. Do not take more often than directed.

Do not stop taking except on your care team's advice.

A special MedGuide will be given to you by the pharmacist with each prescription and refill. Be sure to read this information carefully each time.

Talk to your care team about the use of this medication in children. Special care may be needed.

Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.

What if I miss a dose?

If you miss a dose, take it as soon as you can. If it is almost time for your next dose, take only that dose. Do not take double or extra doses.

What may interact with this medication?

Alcohol

Bosentan

Certain medications for seizures like carbamazepine, phenobarbital, phenytoin

Rifabutin

Rifampin

St. John's Wort

Sulfonylureas like glimepiride, glipizide, glyburide

This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.

What should I watch for while using this medication?

Visit your care team for regular checks on your progress.

A test called the HbA1C (A1C) will be monitored. This is a simple blood test. It measures your blood sugar control over the last 2 to 3 months. You will receive this test every 3 to 6 months.

Learn how to check your blood sugar. Learn the symptoms of low and high blood sugar and how to manage them.

Always carry a quick-source of sugar with you in case you have symptoms of low blood sugar. Examples include hard sugar candy or glucose tablets. Make sure others know that you can choke if you eat or drink when you develop serious symptoms of low blood sugar, such as seizures or unconsciousness. They must get medical help at once.

Tell your care team if you have high blood sugar. You might need to change the dose of your medication. If you are sick or exercising more than usual, you might need to change the dose of your medication.

Do not skip meals. Ask your care team if you should Avoid alcohol. Many nonprescription cough and cold products contain sugar or alcohol. These can affect blood sugar.

Wear a medical ID bracelet or chain, and carry a card that describes your disease and details of your medication and dosage times.

What side effects may I notice from receiving this medication?

Side effects that you should report to your care team as soon as possible:

Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat

Heart failure—shortness of breath, swelling of the ankles, feet, or hands, sudden weight gain, unusual weakness or fatigue

Pancreatitis—severe stomach pain that spreads to your back or gets worse after eating or when touched, fever, nausea, vomiting

Redness, blistering, peeling or loosening of the skin, including inside the mouth

Severe joint pain

Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):

Cough

Diarrhea

Runny or stuffy nose

Sore throat

Where should I keep my medication?

Keep out of the reach of children.

Store at room temperature between 15 and 30 degrees C (59 and 86 degrees F). Throw away any unused medication after the expiration date.

[shlipayadavblog]

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos

Multinational drug major Boehringer Ingelheim (BI) has obtained ad-interim injunctions against four domestic pharmaceutical companies -- Eris Lifesciences, Emcure Pharma, Optimus Pharma and MSN Laboratories. These companies had launched generic versions of Boehringer Ingelheim’s patent-protected drug Linagliptin, which is marketed under the brand name Trajenta.

The company also secured injunctions against Dr Reddy's Laboratories (DRL) and MSN Laboratories earlier for its diabetic drug Empagliflozin marketed as Jardiance in India.

Also, the company had secured an ad-interim injunction against Macleods Pharma for its Linagliptin drug, which was eventually made absolute.

"The recent injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making, using, offering for sale, selling, importing and/or exporting in any form in India either by themselves or through their directors, partners licenses, stockist and distributors, agents etc., jointly and severally until the next date of hearing," BI said in a statement here.

[kumarshivam]

Treatment Options for Type 2 Diabetes

Diabetes and prediabetes are two of the country's most serious health problems. Over 1.33 billion people in India are diagnosed and suffering with diabetes.

When blood sugar levels are higher than usual but not yet high enough to be diagnosed as type 2 diabetes, it is called prediabetes. Weight loss and greater activity can help you avoid being diagnosed with type 2 diabetes.

The number of Americans at risk for these disorders is even more alarming: the American Diabetes Association revealed that out of 34.2 million individuals with diabetes, 26.8 million were diagnosed and 7.3 million remained undiagnosed. The best Diabetic specialist kolkata will provide you with the best recommendations for type-2 diabetes treatment. 

Type 2 Diabetic Treatment

Type 2 diabetes has no cure, but patients may control their symptoms by eating well, staying active through regular exercise, and maintaining a healthy weight. But there are instances when this isn't enough.  Changing your lifestyle is one of the best ways to control your diabetes and not let it get out of control. 

Oral metformin, a medicine that forms the backbone of oral diabetes treatment regimens, is frequently the first drug used to treat type 2 diabetes. Different medication types may be added to metformin after that, and injectable insulin may be required for certain people.

Insulin is a hormone that allows the body to use glucose (sugar) from food to create energy.

The pancreas does not produce insulin in type 1 diabetes, thus it must be supplemented. In type 2 diabetes, the pancreas either does not produce enough insulin, or the effects of insulin are resistant, or both. The best Diabetic specialist  kolkata will provide you with the best recommendations for type-2 diabetes treatment depending on several factors. 

Medication For Diabetes Treatment

Sulfonylurea

Glipizide, glyburide, and glimepiride are examples of medications in this class. These drugs are affordable, but they can induce low blood sugar and weight gain.

Insulin Sensitizer

Pioglitazone is a medicine that is effective and does not cause hypoglycemia (low blood sugar). It can, however, result in weight gain. The best Diabetic specialist kolkata will provide you with the best recommendations for type-2 diabetes treatment. 

Agonists for the glucagon-like peptide-1 (GLP-1) receptor

Exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), and dulaglutide (Victoza, Saxenda) are examples of this drug (Trulicity). Some of these drugs are injected daily, while others are injected once a week.

Semaglutide is also available in an oral version (Rybelsus) that may be taken once a day. This sort of medicine is effective and may aid with weight loss as well as heart health. However, it is possible that it will induce adverse effects such as nausea and diarrhea.

Inhibitors of dipeptidyl peptidase-4 (DPP-4 inhibitors)

This category includes a number of drugs. Sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), and vildagliptin (Vildagliptin) are all brand-name medications (Galvus).

Factors Considered By Diabetic Specialists before Recommending Treatment

Your doctor will evaluate the following considerations when deciding which treatment plan is best for you:

Heart disease, such as a history of heart attacks, strokes, or congestive heart failure, is present or absent.

Chronic kidney disease (CKD) is present or absent (CKD)

Potential side effects of diabetes treatment

Cost of medication and treatment

Individual preferences for a treatment plan

Wrapping Up!

Type 2 diabetes is a chronic and complicated disease. Managing it successfully entails employing a variety of risk-reduction methods while also attaining your blood sugar control goals. The best Diabetic specialist kolkata will provide you with the best recommendations for type-2 diabetes treatment depending on several factors. 

[mediseller-international]

Trajenta 5, it's uses, Side effects, and Risk factors

Trajenta 5 is the brand name under which Boehringer Ingelheim sells the drug Linagliptin. It is also known as Tradjenta, Trazenta, and Trayenta. Linagliptin improves glycemic control in adults.is the brand name under which Boehringer Ingelheim sells the drug Linagliptin. It is also known as Tradjenta, Trazenta, and Trayenta. Linagliptin improves glycemic control in adults.

Read on to know more about Trajenta 5, its uses, side effects, risk factors, and more.

Overview

Linagliptin, the chief component drug in Trajenta, is an antidiabetic drug developed by Boehringer Ingelheim to treat type 2 diabetes in adults. In 2011, the FDA approved its use for the same.

Uses

Trajenta 5 is used to treat Type 2 diabetes mellitus alongside proper diet and exercise.

How does Trajenta 5 work?

Trajenta 5 contains Linagliptin, which acts as a dipeptidyl peptidase-4 inhibitor. It increases the production of insulin and subsequently reduces the production of glucagon in the pancreas.

Trajenta also reduces the production of glucose in the liver in case of high blood sugar levels.

Side Effects

Commonly reported side effects of Tradjenta are:

Rtuffy nose

Runny nose

Sore throat

Nausea

Abdominal Discomfort

Dizziness

These mild side effects usually resolve as your body acclimates to the drug.

Serious side-effects reported include:

Muscle pain

Hypoglycemia

Joint aches

Rashes

Anemia

Inflammation in the pancreas, pancreatitis

Discontinue Trajenta 5 and seek medical help if you notice any of these severe side effects.

Risks to consider

Hypoglycemia: Avoid consuming other medicines that reduce blood sugar levels as it may cause hypoglycemia. Talk to your doctor if you are undergoing insulin therapy or currently taking any antidiabetic drugs.

Revere joint pain: If you find yourself having consistent and severe joint ache, do not abruptly discontinue Tradjenta. Your doctor will help you decide the appropriate option for you to undertake.

llergic reactions: Trajenta might cause severe allergic reactions. Seek medical help immediately if you show symptoms such as rashes, raised red patches, swelling of your face, lips, or throat.

Avoid fasting or skipping meals while on Trajenta.

If you have a history of pancreatitis or are currently suffering from it, inform your doctor about it.

If you are pregnant or plan on getting pregnant or are lactating, consult your doctor to weigh the benefits and consequences of taking Trajenta.

Inform your doctor if you have had gallstones, heart failure, kidney problems, or other severe illnesses.

Avoid driving while on medication as Trajenta might cause blurry vision, dizziness, or drowsiness.

Rifampin interacts with Trajenta.

Stress: Managing blood sugar levels while under stress is an arduous task. Trajenta may fail to control your blood sugar levels if you are under stress.

Trajenta shouldn't be used to treat patients affected by Diabetes Type 1.

Dosage and administration

Trajenta 5 is administered orally in tablet form.

The recommended dose is 5mg of Trajenta once a day.

In case you miss a dose, take the tablet whenever you remember. But if you forget about it for the day, do not double it up on the next day.

If you overdose, seek medical help immediately.

Bottom Line

Trajenta 5 is an effective drug to control type 2 diabetes mellitus in adults. Be sure to go through the side effects and risks associated with Trajenta 5 before taking it.

Remember, if your doctor has prescribed you Trajenta 5, they have checked the pros and cons the drug might cause.

To buy Trajenta 5 at the best prices, click here.

For More Information of Healthcare Products

please contact Following us:

Phone Number:   +91-9773529259,  +91-7303072644 E-mail:                 info@mediseller.com                             medisellers.india@gmail.com Visit Website:      https://www.mediseller.com/

[pharmaphorumuk]

Lilly and Boehringer rejig diabetes alliance as Jardiance soars

Eli Lilly and Boehringer Ingelheim have changed the terms of their diabetes alliance to focus their energies on developing their big-selling Jardiance pill.

Under the terms of the original alliance signed in 2011, the companies were to collaborate on Jardiance (empagliflozin), an SGLT-2 inhibitor class drug that went on to revolutionise treatment of diabetes after it showed a cardiac safety benefit in high-risk patients.

The agreement also covered what turned into Basaglar (insulin glargine), a biosimilar of Sanofi’s big-selling Lantus for type 2 diabetes, and Trajenta (linagliptin), a DPP-4 class drug that provides an alternative method for people with diabetes to control their blood sugar levels.

With the revised agreement, which comes into effect on 1 January, the companies said they had “revised their margin sharing structure”, without providing further details.

The alliance will focus expertise and investment in developing and marketing Jardiance, with Boehringer taking over as strategic lead for Trajenta, and Lilly taking responsibility for Basaglar.

Lilly said there would be no changes to 2019 financial guidance, or 2020 financial goals as a result of the amended agreement.

The impact on the upcoming year will be incorporated into Lilly’s 2020 guidance, due to be issued on 17 December 2019.

The net result of the revised margin sharing structure is not expected to be “financially material”,  over the duration of the agreement, the companies said in a joint statement.

Jardiance is propping up Boehringer’s balance sheets, generating annual sales of more than $2 billion for the German pharma last year, up 52.5% compared with 2017.

Lilly has also benefited from Jardiance’s success, seeing its revenues increase 47% to more than $658 million thanks to the alliance.

Although the market for diabetes drugs is fiercely competitive, Jardiance gained a substantial advantage when it became the first to show reduced risk of cardiovascular events in high-risk type 2 diabetes patients in the EMPA-REG OUTCOME trial in late 2015.

Now the most commonly prescribed SGLT-2 class drug Lilly and Boehringer want to build on Jardiance’s success so far with trials ongoing in people with heart failure or chronic kidney disease, including those with and without type 2 diabetes.

Carine Brouillon, head of global therapeutic areas at Boehringer Ingelheim, said: “The alliance has experienced significant success since its formation in 2011, with Jardiance, Trajenta and Basaglar becoming strong brands and continuing to grow in their respective classes globally.

“As the versatility of the SGLT2 inhibitor class continues to be realised, focusing our combined expertise and investment to support this important treatment will not only result in greater value for both companies but better enable us to help more people with and without type 2 diabetes.”

The post Lilly and Boehringer rejig diabetes alliance as Jardiance soars appeared first on .

from https://pharmaphorum.com/news/lilly-and-boehringer-rejig-diabetes-alliance-as-jardiance-soars/

[sherristockman]

Diabetes Meds Are Infecting Genitals With Flesh-Eating Bacteria Dr. Mercola By Dr. Mercola The number of individuals suffering from diabetes continues to rise. In 2012, 20 million Americans had diabetes or prediabetes.1 According to the Centers for Disease Control and Prevention (CDC),2 the number is now over 30 million. This includes 23.1 million diagnosed and 7.2 million who are unaware of their condition. Statistics also indicate there are 84.1 million adults with prediabetes. Interestingly, the estimated percentage of those with Type 1 diabetes has remained stable at 5 percent.3 Total medical costs and lost work and wages are estimated at $245 billion, and the risk of death for adults with diabetes is 50 percent higher than for nondiabetic adults.4 The rapid rise in prevalence strongly suggests Type 2 diabetes is not due to genetics. Insulin and leptin resistance are the foundational causes of diabetes. High blood sugar is merely a symptom thereof. It is essential to make a point of discussing this condition frequently, as it is one of the greatest health threats facing much of the world, while also being one of the easiest to treat with simple lifestyle strategies. However, while many physicians recommend dietary modifications, most individuals begin using oral and injectable hypoglycemic drugs to control blood sugar without addressing the underlying cause. The U.S. Food and Drug Administration (FDA) recently warned that a class of oral medications increases a diabetic’s risk of a rare but life-threatening bacterial infection.5 FDA Warns Diabetes Drug May Be Linked to Serious Genital Infection The infection, called Fournier's gangrene, occurs in the genital area of men and women. The bacteria usually enter the body through a cut and quickly spread. A diagnosis of diabetes is a risk factor for developing Fournier's gangrene. The class of medication associated with an increased risk are sodium-glucose cotransporter-2 (SGLT-2) inhibitors. The infection causes necrotizing fasciitis, or flesh eating disease, of the vaginal area in women and the area between the scrotum and anus in men. The FDA warns patients to seek immediate medical attention if they experience any symptoms of tenderness, redness or swelling or have a fever above 100.4 Fahrenheit (F). The symptoms worsen quickly, so it is vital to seek immediate treatment. In the five years between March 2013 and May 2018, the FDA identified 12 cases of patients taking the medication who developed the infection. They acknowledge these numbers only include reports submitted to the FDA and found in the medical literature. The real number may be higher. According to the FDA:6 “[T]here may be additional cases about which we are unaware. In 2017, an estimated 1.7 million patients received a dispensed prescription for an SGLT-2 inhibitor from U.S. outpatient retail pharmacies. Although most cases of Fournier’s gangrene have previously been reported in men, our 12 cases included seven men and five women. Fournier’s gangrene developed within several months of the patients starting an SGLT-2 inhibitor and the drug was stopped in most cases. All 12 patients were hospitalized and required surgery.” The FDA found one patient had died and others required multiple disfiguring surgeries to stem the infection.7 As diabetes increases the risk of Fournier’s gangrene, the data were analyzed for patients who were taking glucose-lowering agents.8 The infection is more typically found in men ages 50 to 60.9 The SGLT-2 inhibitors are a class of hypoglycemic drugs designed to work against SGLT-2, a low affinity, high capacity transporter protein found in the kidneys. This class of medication was approved as an adjunct to diet and exercise to improve glycemic control in Type 2 diabetes and not for use in Type 1 diabetes. These are the brand name and generic names of the drugs currently on the market:10,11 Canagliflozin (Invokana) Dapagliflozin (Farxiga) Empagliflozin (Jardiance) Empagliflozin/linagliptin (Glyxambi) Empagliflozin/metformin (Synjardy) Dapagliflozin/metformin (Xigduo XR) Ertugliflozin (Steglatro) Infection Is Not the Only Concern With SGLT2 Inhibitors Besides several safety communications that included concerns about increased risks of leg and foot amputations,12 this was the second safety warning the FDA issued against SGLT-2 inhibitors. May 15, 2015,13 the FDA issued a warning the drugs may lead to ketoacidosis, a condition in which the body produces high levels of acids often requiring emergency care or hospitalization for treatment. In a search of the FDA Adverse Event Reporting System (FAERS), they identified 20 cases of diabetic ketoacidosis associated with the medications. Each patient required an emergency room visit or hospitalization for treatment. The FDA recommended discontinuing the drug if acidosis was confirmed, and instituting supportive medical care.14 The FDA found triggering factors in some cases included acute illnesses, such as urinary tract infections, gastroenteritis or the flu.15 Other patients found a reduced caloric or fluid intake and reduced insulin dosing could trigger diabetic ketoacidosis while taking the medication. One month after the FDA announcement, the European Medicines Agency (EMA) also announced an investigation into the risk of diabetic ketoacidosis with SGLT-2 inhibitors.16 Health Canada quickly followed. The EMA decision was prompted by their adverse events reporting database indicating more than 100 people suffered from diabetic ketoacidosis while using SGLT-2 inhibitors, serious enough to require hospitalization. By the end of the year the FDA safety review prompted the addition of printed warnings on all labeling regarding the risk. They also included risks regarding life-threatening blood infections (sepsis) and kidney infections that began as urinary tract infections in people taking SGLT2 inhibitors.17 Diabetes Drugs Affect More Than Blood Sugar There are nine classes of oral diabetes drugs, all of which differ in their side effect profiles. Some of the other known side effects of SGLT-2 inhibitors include vaginal yeast infections and yeast infections of the penis, upper respiratory tract infections, urinary tract infections and changes in patterns of urination. Others have reported hypotension, kidney dysfunction, bladder cancer and hypersensitivity reactions.18 The surge in new drug classes to treat Type 2 diabetes has been fueled by the rising number of individuals suffering from the disease. Drug companies are quick to step in and fill a growing desire for quick treatments, often leaving consumers to experience the side effects of taking a pill rather than changing their diet and lifestyle. Many of these drugs also interfere with other medications you may be taking, including several heart medications and antibiotics. Injectable insulin plays a unique role in the exacerbation of diabetes, which I discuss in a previous article, “How to Reverse Type 2 Diabetes, Why Insulin May Actually Accelerate Death, and Other Ignored Facts.” Potential side effects from various oral medications include the following:19 Thiazolidinediones — Liver disease, fluid retention, weight gain and increased risk for fractures and bladder cancer DPP-4 inhibitors — Hypoglycemia, fluid retention, hives, urinary tract infection and facial swelling Biguanides — Stomach discomfort, diarrhea, decreased appetite, interference with B12 absorption and exercise-induced hypoglycemia Sulfonylureas — Skin rashes, reduced red blood cell count, liver disease and upset stomach A-glucosidase — Gas, bloating and diarrhea Bile acid sequestrants — Stomach discomfort or pain, constipation and heartburn Bromocriptine mesylate — Nausea, headache, weakness, dizziness, sinusitis and constipation Diabetes Triggers Long-Term Damage to Organ Systems In the long term, high glucose levels, which are the result of insulin resistance, damage large and small blood vessels, ultimately leading to an increased risk for heart attack and stroke, as well as problems with the kidneys, eyes, feet and neurological systems.20 It is also possible to experience nerve damage to internal organs, such as the stomach, intestines, bladder and genitals. These may result in digestive issues, urinary tract conditions and sexual dysfunction.21 Damage to small blood vessels also increases the risk of frequent infections and problems with wounds that will not heal. Nerve damage in the hands, feet or arms, called diabetic neuropathy, affects nearly half of those with diabetes and is more common in those who have had the disease for a number of years. Symptoms range from pain and numbness in the feet or hands to problems with function with internal organs, such as your heart and bladder.22 Autonomic neuropathy damages nerves controlling your internal organs, while focal neuropathy typically damages a single nerve, often in your hand, head or leg. Proximal neuropathy is rare and disabling, causing nerve damage to your hip or thigh and often affecting only one side of your body. The good news is the risk of these kinds of complications can be reduced by making lifestyle changes to improve your insulin and leptin sensitivity. Medical Treatments Don’t Treat the Condition Conventional medicine has pegged Type 2 diabetes as a problem with blood sugar control, and the medical goal of treatment is to reduce blood glucose levels in order to prevent blood vessel damage. However, as diabetes is primarily triggered by a seriously flawed diet and lack of physical activity, prescriptions to address blood sugar levels fail to address the root cause. In other words, the medical community’s approach is to treat the symptom of elevated blood sugar and not the condition of malfunctioning insulin and leptin signaling, and to use medications that come with their own long list of side effects that impact a number of bodily systems. Lifestyle Strategies That Address the Root Cause of Diabetes You do not have to become a part of the diabetes epidemic taking place in the world today. You merely have to be mindful of your everyday habits. Your body is a complex combination of chemicals, enzymes and hormones and, while it may be tempting to believe one hormone controls an entire system, the reality is far more intricate. There is no question that regularly consuming excessive amounts of net carbs dramatically increases your risk, and consuming too much processed fructose will inevitably wreak havoc on your body's ability to regulate proper insulin levels. Although refined fructose initially has a relatively "low glycemic” profile, it leads to chronic insulin resistance and elevated blood sugar long-term. So, while you may not notice a steep rise in blood sugar immediately following fructose consumption, it is likely changing your endocrine system's ability to function properly behind the scenes. Here are several simple and effective choices to naturally help your body control insulin resistance and sensitivity. Increase your fiber intake — Include both soluble and insoluble fiber in your daily diet. Grains, even organic ones, are not an ideal source of fiber. Instead, eat more organic whole, unsweetened husk psyllium, chia seeds, sprouts and vegetables such as broccoli, cauliflower and Brussels sprouts. Aim to include 50 grams of fiber for every 1,000 calories you eat daily. Reduce net carbs — A low-net carbohydrate diet reduces inflammation and the amount insulin required to use the energy from the food you eat. Aim for 50 grams of net carbs per day. This number is calculated by taking the grams of carbs you've eaten and subtracting the number of grams of fiber. In this way a high-fiber diet also helps you to lower the amount of insulin you need to utilize your food for fuel. Increase high-quality fats — When you reduce carbohydrates, your best alternative to replace them is high-quality, healthy fats necessary for keeping your heart healthy, feeding your brain, modulating genetic regulation and prevent cancer. Healthy fat sources include: Avocados Coconut and olive oil Organic, grass fed meat and dairy products such as butter Organic raw nuts Exercise — Exercise is a diabetic’s best ally, and can produce rather rapid results. Research23 published in Medicine & Science in Sports & Exercise found, for example, that a single session of moderate exercise can improve the way your body regulates glucose and reduces the spikes in blood sugar that occur after a meal (elevations in these spikes, known as postprandial glucose, or PPG, are associated with Type 2 diabetes, heart disease and death). When you exercise for diabetes prevention or treatment, intensity is key. A slow walk around the block, while better than watching TV on the couch, is not likely to cut it (although if you're morbidly obese and very out of shape this is a good way to start). Instead, high-intensity interval training, which is a core component of my Peak Fitness program, should ideally be included in your fitness program to achieve optimal results. Hydration — As you become dehydrated, your liver secretes a hormone that increases your blood sugar.24 As you hydrate, blood sugar levels lower naturally. To stay well-hydrated drink enough to maintain your urine color straw yellow throughout the day. Reduce stress — Stress increases the secretion of cortisol and glucagon, both of which affect your blood sugar levels.25,26 Control your stress levels using exercise, meditation, yoga, prayer or Emotional Freedom Techniques (EFT). Sleep — Getting enough quality sleep is necessary to feel good and experience good health. Poor sleeping habits may reduce insulin sensitivity and promote weight gain.27,28

[healthy-insights]

Antidiabetics Market Research Report: Forecast up to 2023

The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.

The anti-diabetics market has been segmented based on type of drug class into biguanides (metformin), sulfonylureas (glimepiride), meglitinides (repaglinide), thiazolidinediones (pioglitazone), dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin), and α-glucosidase inhibitors (acarbose).

Among these drug classes, Biguanides act directly against insulin resistance. Sulfonylureas (SUs) were the earliest drug classes in the market for treatment of diabetes and have a significant market presence. α-glucosidase inhibitors delay postprandial glucose absorption by hydrolysis of disaccharide is into monosaccharide’s in the small intestine. Meglitinides are prandial insulin releasers that stimulate rapid insulin secretion. The thiazolidinediones are insulin-sensitizing drugs, which improve whole-body insulin sensitivity through gene regulation. DPP-IV inhibitors make a significant impact on glucose tolerance and make lasting improvements in the health outcomes of diabetic patients.

Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II.

View Report-

http://www.transparencymarketresearch.com/antidiabetics-market.html

 Some of the key opportunities for the antidiabetics include a strong pipeline for antidiabetics and entry of new players in the market, for instance, Novo Nordisk's diabetes drug’s Tresiba, and Ryzodeg received FDA approval in September 2015. Moreover, Boehringer Ingelheim GmbH has a strong pipeline for anti-diabetic drugs, such as Linagliptin which is a dipeptidyl peptidase (DPP) 4 inhibitor) for patients suffering from diabetes mellitus type II and high cardiovascular risk.

However, despite the availability of numerous branded antidiabetic drugs, many of these drugs have lost patent protection. In the wake of huge pressures from government and regulatory authorities, which have banned top selling drugs in various countries, in order to promote generic drugs at lower costs for diabetic patients. For instance, Mankind Pharma, launched anti-diabeticDynaglipt (Teneligliptin) under the drug class DPP-4 inhibitors in November 2015 in India targeting the middle to low income diabetic patient population.

As a result, the volume of antidiabetics is expected to shift to first generation drugs and other generic drugs in the market. Moreover, there is a huge unmet medical need for antidiabetics that can treat multiple chronic disorderscoexisting with diabetessuch as cardiovascular diseases, dyslipidemia, hypertension etc. Another major restraint in the antidiabetics market is reduction in the efficacy of drugs over a period and canlead to other health complications.

Some of the major players in the market include Astra Zeneca plc, Boehringer Ingelheim GmbH, Eli Lilly & Co., Johnson & Johnson, Mankind Pharma Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, SanofiS.A., and Teva Pharmaceutical Industries Ltd.

 Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Antidiabetics Market during 2015- 2023

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8809

 About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

[type2diabetestreatments-blog]

And Along Came Tradjenta... Or, The Wacky World of Type 2 Drugs

New Post has been published on https://type2diabetestreatment.net/diabetes-mellitus/and-along-came-tradjenta-or-the-wacky-world-of-type-2-drugs/

And Along Came Tradjenta... Or, The Wacky World of Type 2 Drugs

The world of type 2 diabetes drugs is wacky indeed. While Amylin's long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.

The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that can be combined with other BG-lowering meds, especially metformin.

Upon its release, Amylin promptly filed a lawsuit against Eli Lilly, its partner in developing Bydureon, accusing Lilly of violating federal laws and engaging in anti-competitive practices because "Tradjenta would be a direct competitor for Byetta (exenatide), and Eli Lilly would be able to use the same marketing people on both drugs, giving it the ability to choose which drug is promoted better."

Eli Lilly has denied the charges, stating that Tradjenta will not compete with Byetta, therefore the company "has committed no crime in allying itself with Boehringer Ingelheim." But then yesterday, a U.S. District Court upheld a restraining order banning Lilly from proceeding with its plans to use the same sales force to sell both drugs.

According to David Kliff of Diabetic Investor, an industry-watcher who knows the in's and out's of the Diabetes Pharma World as well as anyone, "Tradjenta is basically the same drug as Januvia, with some very slight differences... (and) there is no compelling reason for a physician to prescribe Tradjenta over Januvia." He also states that "the vast majority of A1C lowering (effect) comes when Januvia is used in combination with metformin; take away the metformin and you have a rather lackluster drug with a suspect safety profile."

Just a moment there: Januvia competes with Byetta, so of course it stands to reason that Tradjenta will too.

Meanwhile, Januvia also competes with Victoza, another injectable GLP-1 drug from Novo Nordisk, and Onglyza, a once-daily DPP-4 inhibitor pill from Astra Zeneca.

This is confusing as all get-out, if you ask me.

Do the injectables really compete with the oral drugs? And why does it seem that most type 2s are prescribed multiple glucose-lowering medications?

I needed a refresher, so I looked up some of the terms once again and made myself some notes, which will hopefully be useful to you all scratching your heads at home as well:

* DPP-4 inhibitor drugs are taken orally. They lower blood sugar by inhibiting glucagon release, versus...

* GLP-1 receptor drugs (like Byetta), taken by injection. They work to lower your blood sugar in three ways: enhancing insulin secretion, suppressing glucgon release, and gastric emptying.

Who Owns What

Januvia (Merck) — oral DPP-4, direct competitor to Byetta that is reportedly doing better in the market.

Janumet (Merck) - a combo of oral drugs Januvia and metformin, designed to help patients cut down on pill-popping. There are other combo drugs in the works, too.

Victoza (Novo Nordisk) — injectable GLP-1 drug designed to stimulate insulin secretion when hyperglycemia (high blood sugar) is present. Supposedly causes fewer/ less unpleasant side effects than competitors; much-discussed among patients. See our default user forum (721 comments and counting!)

Onglyza (Astra Zeneca) — a once-daily tablet DPP-4 inhibitor, competes with Januvia; according to some, it's like Januvia but worse.

Bydureon (Amylin & Lilly) - that GLP-1 long-acting version of Byetta (Amylin) with the potential to be a blockbuster, although studies show it's not as good as Victoza.

What's Different About Tradjenta

It seems the only real differentiator here is the dosing — a single 5mg once-daily to remember for all patients, "regardless of kidney or liver impairment" (not the case with competing drugs).

This is so because Tradjenta, uniquely among DPP-4 drugs, is "not expressed through the kidney but rather through the bile and gut — 95% of it, anyway."

Medical Marketing & Media reports that Tradjenta "has a tough climb ahead of it" because it's coming out third-to-market in its drug class, behind "entrenched category leader" Januvia, which racks up billions in sales.

An "Ideal Diabetes Drug"?

Is there such thing as a single "ideal drug" for type 2 diabetes?

According to Kliff, the famous Dr. Anne Peters of the USC Clinical Diabetes Program recently made this statement:

"My ideal diabetes drug lowers blood glucose, helps reduce weight, improves cardiovascular risk factors, and preserves beta cells — and costs $4 a month."

Kliff's reaction?

"Take away the $4 per month cost and what Dr. Peters is describing is actually here today and called a GLP-1. Notice that nowhere in her comments does Dr. Peters mention anything about how this ideal drug would be administered (oral versus injection). ... Although not 'perfect,' a GLP-1 also has additional benefits beyond lowering blood glucose, helping reduce weight, improving cardiovascular risk factors and preserving beta cells."

He also states that "patients can actually see and feel a benefit from using (a GLP-1), something that does not happen with metformin or a DPP-4."

Our Type 2 Friends out there: please share your experiences taking the orals versus injectables. Also, anyone involved in Tradjenta studies or tried this new drug yet?

Disclaimer: Content created by the Diabetes Mine team. For more details click here.

Disclaimer

This content is created for Diabetes Mine, a consumer health blog focused on the diabetes community. The content is not medically reviewed and doesn't adhere to Healthline's editorial guidelines. For more information about Healthline's partnership with Diabetes Mine, please click here.

Type 2 Diabetes Treatment Type 2 Diabetes Diet Diabetes Destroyer Reviews Original Article

[siglerprescriptiondrugcards]

Linagliptin

Brand Name: Tradjenta

Common Dosage Forms:

Tablets: 5 mg

FDA Indications/Dosages:

As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus: 5 mg taken once daily.

When used with an insulin secretagogue (sulfonylurea) or with insulin, use a lower dose of the insulin secretagogue or insulin to decrease the risk of hypoglycemia.

Monitor: FBG, HbA1C

Pharmacology/Pharmacokinetics: Linagliptin inhibits the dipeptidyl peptidase-4 (DDP-4) enzyme. DDP-4 is responsible for deactivating the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are released by the intestine in response to food and are credited with increasing insulin synthesis and release from pancreatic beta cells. GLP-1 also decreases hepatic glucose production by lowering glucagon secretion from pancreatic alpha cells. By inhibiting DDP-4, linagliptin increases insulin and decreases glucagon in response to elevated blood glucose. Inhibition of DDP-4 by sitagliptin lasts for 24 hours. Peak plasma levels are reached in 1.5 hours. Approximately 85% is excreted in the urine as unchanged drug. The terminal half-life after an oral dose is approximately 12 hours.

Drug Interactions: Strong inducers of CYP3A4 or P-gp (rifampin) may decrease effectiveness.

Contraindications/Precautions: Contraindicated in patients with known or suspected hypersensitivity to linagliptin. Increases the risk of acute pancreatitis (upper abdominal pain, nausea and vomiting, fever). Use caution when combining with medications known to cause hypoglycemia. Hypersensitivity reactions have occurred within 3 months of starting therapy. Pregnancy Category B.

Adverse Effects: Adverse effects are uncommon and mild and include nasopharyngitis, diarrhea, and cough. A rare adverse effect seen with other DDP-4 inhibitors is joint pain (arthralgia). Rare but severe cases of hypersensitivity and pancreatitis have been reported.

Patient Consultation:

May be taken without regard to meals.

Closely follow recommended dietary and exercise instructions.

Quarterly HbA1c testing should be performed.

Store in a cool, dry place away from sunlight and children.

If a dose is missed, take it as soon as possible but do not double doses.

Call physician is above side effects are severe or persistent.

[healthy-insights]

Antidiabetics Market Research Report: Forecast up to 2023

The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.

The anti-diabetics market has been segmented based on type of drug class into biguanides (metformin), sulfonylureas (glimepiride), meglitinides (repaglinide), thiazolidinediones (pioglitazone), dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin), and α-glucosidase inhibitors (acarbose).

Among these drug classes, Biguanides act directly against insulin resistance. Sulfonylureas (SUs) were the earliest drug classes in the market for treatment of diabetes and have a significant market presence. α-glucosidase inhibitors delay postprandial glucose absorption by hydrolysis of disaccharide is into monosaccharide’s in the small intestine. Meglitinides are prandial insulin releasers that stimulate rapid insulin secretion. The thiazolidinediones are insulin-sensitizing drugs, which improve whole-body insulin sensitivity through gene regulation. DPP-IV inhibitors make a significant impact on glucose tolerance and make lasting improvements in the health outcomes of diabetic patients.

Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II.

View Report-

http://www.transparencymarketresearch.com/antidiabetics-market.html

 Some of the key opportunities for the antidiabetics include a strong pipeline for antidiabetics and entry of new players in the market, for instance, Novo Nordisk's diabetes drug’s Tresiba, and Ryzodeg received FDA approval in September 2015. Moreover, Boehringer Ingelheim GmbH has a strong pipeline for anti-diabetic drugs, such as Linagliptin which is a dipeptidyl peptidase (DPP) 4 inhibitor) for patients suffering from diabetes mellitus type II and high cardiovascular risk.

However, despite the availability of numerous branded antidiabetic drugs, many of these drugs have lost patent protection. In the wake of huge pressures from government and regulatory authorities, which have banned top selling drugs in various countries, in order to promote generic drugs at lower costs for diabetic patients. For instance, Mankind Pharma, launched anti-diabeticDynaglipt (Teneligliptin) under the drug class DPP-4 inhibitors in November 2015 in India targeting the middle to low income diabetic patient population.

As a result, the volume of antidiabetics is expected to shift to first generation drugs and other generic drugs in the market. Moreover, there is a huge unmet medical need for antidiabetics that can treat multiple chronic disorderscoexisting with diabetessuch as cardiovascular diseases, dyslipidemia, hypertension etc. Another major restraint in the antidiabetics market is reduction in the efficacy of drugs over a period and canlead to other health complications.

Some of the major players in the market include Astra Zeneca plc, Boehringer Ingelheim GmbH, Eli Lilly & Co., Johnson & Johnson, Mankind Pharma Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, SanofiS.A., and Teva Pharmaceutical Industries Ltd.

Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Antidiabetics Market during 2015- 2023

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8809

 About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

 US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

[healthy-insights]

Antidiabetics Market Research Report: Forecast up to 2023

The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.

The anti-diabetics market has been segmented based on type of drug class into biguanides (metformin), sulfonylureas (glimepiride), meglitinides (repaglinide), thiazolidinediones (pioglitazone), dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin), and α-glucosidase inhibitors (acarbose).

Among these drug classes, Biguanides act directly against insulin resistance. Sulfonylureas (SUs) were the earliest drug classes in the market for treatment of diabetes and have a significant market presence. α-glucosidase inhibitors delay postprandial glucose absorption by hydrolysis of disaccharide is into monosaccharide’s in the small intestine. Meglitinides are prandial insulin releasers that stimulate rapid insulin secretion. The thiazolidinediones are insulin-sensitizing drugs, which improve whole-body insulin sensitivity through gene regulation. DPP-IV inhibitors make a significant impact on glucose tolerance and make lasting improvements in the health outcomes of diabetic patients.

Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II.

View Report-

http://www.transparencymarketresearch.com/antidiabetics-market.html

Some of the key opportunities for the antidiabetics include a strong pipeline for antidiabetics and entry of new players in the market, for instance, Novo Nordisk's diabetes drug’s Tresiba, and Ryzodeg received FDA approval in September 2015. Moreover, Boehringer Ingelheim GmbH has a strong pipeline for anti-diabetic drugs, such as Linagliptin which is a dipeptidyl peptidase (DPP) 4 inhibitor) for patients suffering from diabetes mellitus type II and high cardiovascular risk.

However, despite the availability of numerous branded antidiabetic drugs, many of these drugs have lost patent protection. In the wake of huge pressures from government and regulatory authorities, which have banned top selling drugs in various countries, in order to promote generic drugs at lower costs for diabetic patients. For instance, Mankind Pharma, launched anti-diabeticDynaglipt (Teneligliptin) under the drug class DPP-4 inhibitors in November 2015 in India targeting the middle to low income diabetic patient population.

As a result, the volume of antidiabetics is expected to shift to first generation drugs and other generic drugs in the market. Moreover, there is a huge unmet medical need for antidiabetics that can treat multiple chronic disorderscoexisting with diabetessuch as cardiovascular diseases, dyslipidemia, hypertension etc. Another major restraint in the antidiabetics market is reduction in the efficacy of drugs over a period and canlead to other health complications.

Some of the major players in the market include Astra Zeneca plc, Boehringer Ingelheim GmbH, Eli Lilly & Co., Johnson & Johnson, Mankind Pharma Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, SanofiS.A., and Teva Pharmaceutical Industries Ltd.

Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Antidiabetics Market during 2015- 2023

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8809

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

 US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com